C
rohn's disease (CD) is a chronic, inflammatory bowel disease without a cure. Nearly 1 in 300 individuals living in North America has CD, and it continues to emerge globally with increasing incidence worldwide. 1, 2 The treatment of CD is predominantly directed at inducing and maintaining clinical response and remission, ultimately with the aim of achieving complete mucosal healing. 3 The introduction of biologic agents targeting tumor necrosis factor (TNF) alpha over the past 2 decades has made this a realistic target, even among patients with CD with moderate-to-severe disease. [4] [5] [6] [7] However, up to one-third of patients with CD do not respond to currently available medical therapy, and up to half of patients on anti-TNF therapy will develop an attenuated response. 8, 9 Novel therapeutic options are needed for these patients with difficult-to-treat disease.
Ustekinumab is a fully human IgG 1k monoclonal antibody blocking interleukin (IL)-12 and IL-23 via their common p40 subunit. 10 This disrupts IL receptor-mediated stimulation of T helper (Th)-1 and Th-17 cytokine pathways implicated in CD pathogenesis and inflammation. 11 Results from the phase II Crohn's Evaluation of Response to Ustekinumab Anti-Interleukin-12/23 for Induction (CERTIFI) randomized controlled trial 12 evaluating efficacy of ustekinumab induction and maintenance therapy have recently been corroborated in phase III data from the UNITI-1 and UNITI-2 randomized placebo controlled trials involving 741 and 628 patients with CD, respectively. 13 Feagan et al 13 demonstrated significantly improved 8-week induction response rates with ustekinumab compared with placebo. Furthermore, in the IM-UNITI maintenance study, clinical response was maintained in 59.4% of CD patients receiving subcutaneous ustekinumab every 8 weeks. This robust data has driven the approval of ustekinumab by the Food and Drug Administration, the European Medicines Agency, and Health Canada, for treatment of patients with moderate-to-severe CD.
Before approval, gastroenterologists had limited access to ustekinumab through compassionate release programs. Thus, there remains a paucity of open-label experiences with ustekinumab, particularly for maintenance of response. In the largest experience of 122 ustekinumab-treated patients reported by the Group d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif, the cumulative probability of persistent clinical benefit at 12 months after induction was 68%. 14 Data demonstrating maintenance of objectively defined response by endoscopy or cross-sectional imaging remains lacking, and current studies are limited by small sample sizes and short duration of follow-up.
Therefore, in this study, we assessed the long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in a large, real-life, multicenter open-label cohort of CD patients failing conventional treatment. During maintenance therapy, we evaluated the proportion of patients losing response to ustekinumab, characterized time to loss of response, and evaluated clinical features associated with loss of response in multivariate Cox proportional hazards analysis.
MATERIALS AND METHODS

Study Design and Patient Population
A retrospective observational cohort study was performed at 2 academic tertiary care centers at the University of Calgary, Calgary, Canada, and at the University of Alberta, Edmonton, Canada. Adult patients ($18 yr) with endoscopically and histologically confirmed CD receiving ustekinumab between January 1, 2011 and July 1, 2016 were identified. Patients achieving primary steroid-free clinical response to ustekinumab induction and who were advanced onto a regularly scheduled, subcutaneously administered ustekinumab maintenance treatment regimen were eligible for inclusion.
Response to ustekinumab induction was defined in accordance with the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) definitions. 3 Clinical response was defined by an improvement in symptoms on physician global assessment and decrease in Harvey Bradshaw Index 15 (HBI) of $3 points compared with baseline. Patients failing to achieve steroid-free clinical response within 6 months of induction were excluded. However, patients achieving induction response through dose optimization (via reinduction or dose escalation) before 6 months were still eligible for inclusion.
Outcomes and Definitions
The primary objective of this study was to determine the proportion of patients with CD who lose response to ustekinumab during maintenance therapy among primary responders. Patients were identified as secondary nonresponders (i.e., loss of response during maintenance therapy) based on a composite definition of: (1) worsening clinical symptoms as measured by an increase in HBI .3 points above baseline, and (2) requirement for ustekinumab dose escalation, reinduction, rescue systemic corticosteroids, immunomodulators, surgical intervention, or ustekinumab discontinuation. This composite definition of loss of response has been previously used in open-label cohort studies of biologic therapy for inflammatory bowel disease. 16, 17 Dose escalation or reinduction to optimize induction response among partial primary responders was not considered a loss of response.
As a secondary endpoint, we assessed the objective maintenance of response and remission by endoscopy or cross-sectional imaging. Endoscopic response was defined by an improvement in mucosal inflammation compared with baseline, with absence of deep ulcerations and remission, and was defined by achievement of complete mucosal normalization. Radiographic response was defined by improvement in assessment of bowel wall thickness, inflammatory fat, mural blood flow, and hyperenhancement compared with baseline by physician global assessment of contrast-enhanced ultrasound or computed tomography/magnetic resonance enterography. 18 Radiographic remission was defined by complete normalization of inflammatory parameters on imaging.
The other secondary objectives of this study were to characterize time to loss of response, and to identify clinical factors associated with loss of response. Time to loss of response was determined from the first date of ustekinumab administration to the first date of loss of response; patients maintaining response to the end of follow-up were considered censored cases.
Data Collection
Comprehensive chart review was performed by 2 authors (C.M., N.S.) from 2 sources: (1) physician office-based electronic and paper charts (including clinic letters, nursing and patient correspondence, and outpatient prescriptions), and (2) the regionwide electronic health care database used at both recruitment centers (including inpatient and outpatient laboratory investigations, hospital discharge summaries, and diagnostic imaging, pathology, surgical, and endoscopy reports).
Baseline data collected included gender, age, weight, smoking status, disease duration, disease phenotype (by the Montreal Classification for CD 19 ), previous and concurrent CD treatments (including immunomodulators, anti-TNF therapy, other biologics, and previous surgery), and ustekinumab induction and maintenance dosing.
Statistical Analysis
Baseline characteristics were analyzed with standard descriptive statistics. Medians with IQRs were calculated for continuous data, and proportions were assessed for categorical data. A life table was constructed to assess the cumulative probability of maintained clinical response after induction therapy. A multivariate Cox proportional hazards regression analysis was performed to identify clinical factors associated with loss of response, expressed as hazard ratios (HR) with 95% confidence intervals. Variables for the multivariate analysis were chosen a priori, including gender, body weight ($70 versus ,70 kg), smoking status (current, former, or never smoker at ustekinumab induction), disease activity (HBI $ 7, CRP $ 10 mg/L), disease location (by Montreal Classification as ileal, colonic, or ileocolonic), disease phenotype (by Montreal Classification as inflammatory, stricturing, or penetrating), concurrent medication use (immunomodulators, corticosteroids), and ustekinumab dosing (3 versus 6 mg/kg induction dosing, q8 versus q12 weeks maintenance dosing). The Cox proportional hazards assumption was tested to ensure model assumptions were not violated.
Statistical analysis was performed using SPSS 24.0 statistical software (IBM Corporation, Armonk, NY).
Ethical Considerations
This study was approved by the Human Research Ethics Board at both the University of Calgary and the University of Alberta.
RESULTS
Baseline Patient Characteristics
Patient demographics are summarized in Table 1 . One hundred four patients with CD achieved steroid-free clinical response within 6 months of ustekinumab induction and were included in the cohort. Median follow-up time was 57.2 weeks (IQR: 36.7-103.4 wk). Predominantly, patients had longstanding (median disease duration 13.8 yr, IQR: 9.1-22.9 yr), ileocolonic (57/104, 54.8%), inflammatory phenotype (48/104, 46.2%) disease; 92.3% (96/104) of patients had previously failed anti-TNF therapy, and approximately two-thirds of patients (66/104, 63.5%) had previously required intestinal resection. The median induction dose was 3.5 mg/kg (IQR: 2.5-5.3 mg/kg) administered within the first 4 weeks of therapy. Ninety-one patients (88.3%) received subcutaneous induction; 12 patients (11.7%) received intravenous induction. Primary induction response was successfully optimized by dose escalation in 34 patients (32.7%), and reinduction in 11 patients (10.6%) before inclusion in this cohort.
All patients received subcutaneous 90 mg ustekinumab maintenance therapy: the majority (87/104, 83.7%) received initial maintenance dosing every 8 weeks; 16 patients (15.4%) received ustekinumab maintenance dosing every 12 weeks, and 1 patient initiated maintenance dosing at an initial interval of every 6 weeks.
Loss of Response to Ustekinumab During Maintenance Therapy
Loss of response during maintenance therapy is summarized in Table 2 . The cumulative probability of maintaining clinical response to ustekinumab at 24 and 52 weeks was 95.8% and 71.8%, respectively. Thirty-five (33.7%) patients lost clinical response to ustekinumab maintenance at a median time of 47.4 weeks (IQR: 35.3-68.4 wk) after induction. Dose escalation was required in 17 patients (16.3%), and a combined reinduction with dose escalation strategy was used in 7 patients (6.7%) for loss of response. The most common escalated maintenance dosing was ustekinumab 90 mg subcutaneously every 4 or 6 weeks. Dose escalation effectively recaptured clinical response in 9/17 (52.9%) patients; combined reinduction and escalation was 
Clinical Factors Associated with Ustekinumab Response
In multivariate Cox proportional hazards regression, concurrent immunomodulation (adjusted HR 0.41 (95% confidence interval, 0.17-0.97)), colonic disease (aHR 0.33 (0.11-0.98)), and ileocolonic disease (aHR 0.26 (0.10-0.68)) were associated with lower risk for loss of response during maintenance therapy. In contrast, highly active disease as defined by an HBI $7 at induction (aHR 4.63 (1.64-13.11)) and stricturing disease phenotype (aHR 2.77 (1.10-7.01)) were associated with response attenuation. Adjusted survival curves for the proportion of patients losing response to ustekinumab maintenance therapy are presented in Figure 1 . Gender, tobacco use, patient weight, and ustekinumab induction or maintenance dosing were not significantly associated with loss of response ( Table 3) .
Safety of Ustekinumab for LongTerm Maintenance
Thirty-four patients (32.7%) experienced an adverse event during maintenance therapy. Predominantly, these were infectious complications (12/104, 11.5%) with the majority being mild upper respiratory tract infections. No infections during the maintenance phase of treatment required ustekinumab discontinuation as part of the management plan. Arthralgia was experienced by 13 patients (12.5%). One patient experienced a serious adverse event requiring ustekinumab discontinuation (severe neuropathic pain which resolved after ustekinumab was stopped). No deaths occurred in this cohort, and there were no reported cases of malignancy, lymphoma, tuberculosis, or major adverse cardiovascular events during follow-up. One patient discontinued ustekinumab due to adverse effects, 10 patients discontinued therapy due to loss of response. 
DISCUSSION
Although the advent of biologic therapy has transformed the management of moderate-to-severe CD, patients who are primary or secondary nonresponders to anti-TNF therapy pose a clinical challenge. 20 Novel therapeutic options that are safe and effective not only for inducing, but also for maintaining long-term response are desperately needed for these patients with refractory, complex, phenotype CD. We assessed the maintenance of steroidfree clinical response in this large, multicenter cohort study of over 100 patients with CD responding to ustekinumab induction, most of whom had previously failed anti-TNF therapy and required surgical resection. We demonstrated that two-thirds of patients with CD can maintain this response long-term with ustekinumab, confirmed on endoscopic and radiographic assessment. Only 10% discontinued therapy due to response attenuation.
Two large, prospective, randomized, placebo-controlled trials have assessed the efficacy of ustekinumab for maintaining clinical response in CD. In the CERTIFI phase II study, Sandborn et al 12 evaluated short-term maintenance of response assessed at 22 weeks. Among induction responders, 41.7% of patients receiving ustekinumab maintenance therapy were in clinical remission compared with 27.4% of patients receiving placebo (P ¼ 0.03). Additionally, 55.6% of patients achieved a sustained clinical response, defined by clinical response at every visit during the maintenance phase. 12 These results were further corroborated by the IM-UNITI phase III clinical trial, in which 397 responders from the induction UNITI studies were enrolled and randomized to maintenance ustekinumab or placebo. Maintenance of response at week 44 was achieved in 59.4% of patients receiving ustekinumab every 8 weeks, and 58.1% of patients receiving the drug every 12 weeks. 13 Similarly, approximately two-thirds of patients in our cohort maintained response to the end of follow-up with a cumulative probability for maintaining response of 71.8% at 52 weeks. These results are also comparable with those from 2 open-label, multicenter, retrospective reviews. In the Group d'Etude Thérapeu-tique des Affections Inflammatoires du Tube Digestif cohort of European patients, 23% of initial responders experienced a secondary ustekinumab failure, and the cumulative probability of persistent clinical benefit was 68% at 12 months. 14 In another cohort of 97 Spanish patients with CD responding to ustekinumab induction, Khorrami et al 21 reported the cumulative probability for maintained clinical benefit to ustekinumab was 74% at 12 months. In our cohort as well as in other prospective and retrospective studies, secondary loss of response to ustekinumab appears to be numerically less frequent compared with attenuated anti-TNF response, where the rates of secondary failure can exceed 50%. 16 However, this should be interpreted in the context of shorter follow-up duration in ustekinumab treatment experiences.
The durability of response may relate to low rates of ustekinumab immunogenicity: in the CERTIFI trial, antiustekinumab antibodies were observed in only 3 patients (0.7%), 12 and in the IM-UNITI trial, antibodies developed in only 2.3% of patients as measured by a drug-tolerant assay. 13 Despite low rates of reported ustekinumab immunogenicity, we found that response was better maintained in patients on concurrent immunomodulation in our cohort. Presumably, the moderate effect size of concurrent azathioprine or methotrexate on maintenance of response cannot be explained solely by prevention of such low-level antidrug antibody formation, in contrast to what is observed with anti-TNF therapy. 22, 23 Rather, we hypothesize that the benefit of concurrent immunosuppression may relate to augmentation of ustekinumab drug levels or synergistic anti-inflammatory effects. Unfortunately, therapeutic drug monitoring was not available in our cohort.
In our study, half the patients requiring ustekinumab dose escalation for loss of response recaptured clinical benefit. This is similar to the proportion of patients benefiting from dose escalation, as reported by Kopylov et al, 24 and in the USTEK Study Group cohort where 73% of patients had a positive response. 21 Additionally, one-third of patients in our cohort had One patient received ustekinumab maintenance at every 6-week interval and was excluded from the multivariate analysis. already successfully dose escalated to optimize their primary response to ustekinumab induction therapy. The robust clinical response to dose escalation may suggest that existing treatment regimens have underdosed ustekinumab in maintenance of CD. Currently, no data exists to identify which patients are more likely to benefit from dose escalation, and management of attenuated response is based on clinical judgment. We anticipate that as for anti-TNF therapy, therapeutic drug monitoring with incorporation of pharmacokinetic data in developing a management algorithm for attenuated response will likely become a mainstay of therapy to more accurately identify patients experiencing pharmacokinetic versus pharmacodynamic failure. 25 In our Cox proportional hazards model, stricturing disease behavior was associated with increased risk of loss of response during ustekinumab maintenance therapy, and this may also contribute to improved maintenance of response observed among patients with colonic disease. Typically, patients with CD with stricturing disease have poorer outcomes. Previous studies have suggested that this may relate to timing of medical therapy, as delays to effective control of CD-related inflammation result in cumulative bowel damage and development of fixed fibrostenotic disease for which medical therapy is ineffective. 26 Indeed, our patient population was very mature, with a median time to ustekinumab induction after diagnosis of .10 years. Whether ustekinumab can prevent development of bowel stricturing in patients with CD presenting initially with inflammatory disease, phenotype, or change, the long-term natural history of CD remains unclear.
Only one serious adverse event requiring ustekinumab discontinuation was reported in our cohort in long-term follow-up, adding further to the literature supporting ustekinumab safety. Ustekinumab safety has been particularly well established in the psoriasis population, 27, 28 and although the dosing used in psoriasis is typically lower than doses used in CD, the serious adverse event rate in ustekinumab-treated patients with CD in clinical trials is equivalent to that of placebo. Further, authors publishing open-label experiences with ustekinumab in CD have reported almost no serious adverse events. 14, 24, 29, 30 In fact, arthralgia was the most commonly reported side effect in our maintenance cohort, but it remains unclear if this is truly drug-related or due to unmasking of underlying CD-related arthropathy after discontinuing anti-TNF therapy.
There are some limitations to our study. Primarily, this was a retrospective analysis which introduces the possibility of recall bias. However, we attempted to minimize this by using stringent, wellvalidated definitions of clinical response as described by internationally endorsed recommendations. 3 Additionally, in contrast to many existing open-label retrospective cohorts, we also evaluated objective endoscopic and radiographic data to evaluate response, which is a major strength of our study. Although retrospective application of standardized endoscopy scoring systems such as the Simple Endoscopic Score are not validated or feasible in this type of study, we used definitions of endoscopic and radiographic response that are highly relevant to clinicians in the real-world environment.
A second limitation is that although we used a multicenter design, and report one of the largest and longest experiences with ustekinumab to date, the sample size may still be insufficient to adequately capture and characterize rare outcomes such as surgery and serious adverse events. Third, there was heterogeneity in our cohort with regards to both induction and maintenance ustekinumab dosing and route of administration. Importantly, the majority of patients in our cohort received subcutaneous induction because intravenous administration was not routinely available during the study period. We also included patients receiving maintenance dosing at every 6-, 8-, and 12-week interval. As the approved and available dosing regimens for ustekinumab vary by jurisdiction, we did not exclude patients from our cohort based on dosing alone.
Finally, we defined the inclusion criteria for the study based on clinical response to induction within 6 months of first ustekinumab dose; although other authors have used 3 months as a cutoff, 14 our experience has been that both clinical and endoscopic response to induction therapy is often delayed and not achieved until several months after ustekinumab initiation. Indeed, this observation has also been borne out in the clinical trial data, and we believe our inclusion criteria are valid.
In conclusion, in this large, multicenter, retrospective cohort study, we demonstrate that subcutaneous ustekinumab is an effective and well-tolerated treatment option for maintaining clinical, endoscopic, and radiographic response long-term in patients with CD with moderate-to-severe disease failing anti-TNF therapy. Future studies should elucidate strategies for optimizing long-term ustekinumab response, including the role of therapeutic drug monitoring and concurrent immunosuppression.
